rank,account_name,fit,urgency,total,fit_reason,urgency_reason,urgency_source,trigger_summary,best_fit_trial_title,best_fit_trial_status,best_fit_trial_phase,best_fit_trial_url,best_urgency_trial_title,best_urgency_trial_status,best_urgency_trial_phase,best_urgency_trial_url,sec_matched_total,patent_matched_total,target_roles
1,AstraZeneca,5.0,3.0,22.850412159168872,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus | trial_collaborator: Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | trial_collaborator: Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma,Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma,ACTIVE_NOT_RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT04257578,A Study of AZD0120 in Autoimmune Diseases,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07295847,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
2,"Chongqing Precision Biotech Co., Ltd",5.0,3.0,21.039636039929274,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus | trial_collaborator: Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors | trial_collaborator: A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors,Study of CD19 CAR-T Therapy for Refractory SLE,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07403097,Study of CD19 CAR-T Therapy for Refractory SLE,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07403097,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
3,Yake Biotechnology Ltd.,5.0,3.0,20.924432846120883,CAR-T trial,"NOT_YET_RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,trial_collaborator: Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia | trial_collaborator: A Multicenter Study of CAR-T Cells in Primary Ph+All | trial_collaborator: Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia,Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia,NOT_YET_RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT07370064,Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia,NOT_YET_RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT07370064,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
4,Regeneron Pharmaceuticals,5.0,3.0,20.906915551506973,CAR-T trial,"RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,"trial_collaborator: A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients Wi | trial_collaborator: Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relap | trial_collaborator: PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML",PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT05105152,A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA),RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT05092347,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
5,"Janssen Research & Development, LLC",5.0,3.0,20.85041215425066,CAR-T trial,ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1),clinicaltrials,"trial_collaborator: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleuce | trial_collaborator: Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse | trial_collaborator: MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma","A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy",ACTIVE_NOT_RECRUITING,PHASE3,https://clinicaltrials.gov/study/NCT04923893,A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants,ACTIVE_NOT_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT05022849,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
6,"Kite, A Gilead Company",5.0,3.0,20.841397625398624,CAR-T trial,ACTIVE_NOT_RECRUITING in high urgency phase (PHASE2),clinicaltrials,trial_collaborator: Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) | trial_collaborator: Neurological and Cognitive Dysfunction Following CAR-T Treatment. ICANS and Beyond | trial_collaborator: Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL,Neurological and Cognitive Dysfunction Following CAR-T Treatment. ICANS and Beyond,NOT_YET_RECRUITING,,https://clinicaltrials.gov/study/NCT07375628,Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1),ACTIVE_NOT_RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT05396885,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
7,"CARsgen Therapeutics Co., Ltd.",5.0,3.0,20.73569781941687,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,"trial_collaborator: Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC | trial_collaborator: A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell  | trial_collaborator: Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE","A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus",RECRUITING,EARLY_PHASE1,https://clinicaltrials.gov/study/NCT07339332,"Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE",RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07031713,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
8,Novartis Pharmaceuticals,5.0,3.0,20.719793721157956,CAR-T trial,"RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,trial_collaborator: A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lympho | trial_collaborator: RadiothErapy priMIng for CAR-T,CAR-T Long Term Follow Up (LTFU) Study,RECRUITING,PHASE3,https://clinicaltrials.gov/study/NCT02445222,"Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis",RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT06704269,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
9,Pfizer,4.0,3.0,20.6972052435467,molecule match: elranatamab,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guide | trial_collaborator: Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma | trial_collaborator: A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elra,A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30),RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06215118,A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30),RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06215118,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
10,Kyverna Therapeutics,5.0,3.0,20.67354704740634,CAR-T trial,"RECRUITING in high urgency phase (PHASE2,PHASE3)",clinicaltrials,"trial_collaborator: A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple  | trial_collaborator: CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 | trial_collaborator: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Prog","KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis",RECRUITING,"PHASE2,PHASE3",https://clinicaltrials.gov/study/NCT06193889,"KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis",RECRUITING,"PHASE2,PHASE3",https://clinicaltrials.gov/study/NCT06193889,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
11,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",5.0,3.0,20.66907867960382,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,"trial_collaborator: Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engine | trial_collaborator: BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma | trial_collaborator: A Trial of ""Armored"" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies",Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT06297226,"A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)",RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06220201,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
12,Miltenyi Biomedicine GmbH,5.0,3.0,20.638989955364195,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,"trial_collaborator: CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblas | trial_collaborator: The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR ",CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07361029,CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07361029,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
13,"Guangzhou Bio-gene Technology Co., Ltd",5.0,3.0,20.626565111293143,CAR-T trial,"RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,trial_collaborator: Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML | trial_collaborator: Safety and Preliminary Efficacy of Anti-CDH17 CAR-T Cell Therapy in Patients with CDH17-positive Advanced Soli | trial_collaborator: A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus,Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML,NOT_YET_RECRUITING,EARLY_PHASE1,https://clinicaltrials.gov/study/NCT07338357,Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia,RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT06118788,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
14,"Hebei Senlang Biotechnology Inc., Ltd.",5.0,3.0,20.61060975065365,CAR-T trial,NOT_YET_RECRUITING in high urgency phase (PHASE2),clinicaltrials,trial_collaborator: SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma | trial_collaborator: Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL | trial_collaborator: Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/LBL,SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma,NOT_YET_RECRUITING,EARLY_PHASE1,https://clinicaltrials.gov/study/NCT07234721,Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.,NOT_YET_RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT07244380,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
15,Bristol-Myers Squibb,5.0,3.0,20.59073408403082,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: Study of BMS-986453 in Newly Diagnosed Multiple Myeloma | trial_collaborator: CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis | trial_collaborator: A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients ,"Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies",ACTIVE_NOT_RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT04205409,Study of BMS-986453 in Newly Diagnosed Multiple Myeloma,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07333261,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
16,"Genentech, Inc.",5.0,3.0,20.580043566756437,CAR-T trial,NOT_YET_RECRUITING in high urgency phase (PHASE1),clinicaltrials,"trial_collaborator: Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lym | trial_collaborator: Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MC | trial_collaborator: Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Agg",Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT05633615,"A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)",NOT_YET_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06984341,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
17,"Rui Therapeutics Co., Ltd",5.0,3.0,20.559633612235174,CAR-T trial,NOT_YET_RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of R | trial_collaborator: Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatm | trial_collaborator: RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies,An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease,RECRUITING,EARLY_PHASE1,https://clinicaltrials.gov/study/NCT07241468,RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies,NOT_YET_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07105735,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
18,Genmab,5.0,3.0,20.553857905208773,CAR-T trial,"ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,"trial_collaborator: Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy i | trial_collaborator: Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders | trial_collaborator: Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma",Epcoritamab-CAR T Cells for Large B-cell Lymphomas,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT06458439,Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome,ACTIVE_NOT_RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT04623541,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
19,"Beijing Immunochina Medical Science & Technology Co., Ltd.",5.0,3.0,20.553857904418845,CAR-T trial,NOT_YET_RECRUITING in high urgency phase (PHASE1),clinicaltrials,,Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction,NOT_YET_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07406984,Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction,NOT_YET_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07406984,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
20,"Shanghai Xiniao Biotech Co., Ltd.",5.0,3.0,20.553857903270817,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases | trial_collaborator: CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases | trial_collaborator: Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD1,UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases,NOT_YET_RECRUITING,EARLY_PHASE1,https://clinicaltrials.gov/study/NCT07410377,CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07315087,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
21,Nanjing Legend Biotech Co.,5.0,3.0,20.542418422165376,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases | trial_collaborator: A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | trial_collaborator: A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus,A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06869278,A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM),RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07331272,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
22,AbbVie,5.0,3.0,20.540375003749354,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,"trial_collaborator: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and | trial_collaborator: Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed | trial_collaborator: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma",MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT06414148,"Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia",RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT04872790,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
23,"Gracell Biotechnologies (Shanghai) Co., Ltd.",5.0,3.0,20.53043573097238,CAR-T trial,"RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,"trial_collaborator: GC012F Injection in Refractory Idiopathic Inflammatory Myopathy | trial_collaborator: This Study is an Open-lable, Phase I Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary  | trial_collaborator: GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)","Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis",RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07250269,A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma,RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT06235229,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
24,Merck Sharp & Dohme LLC,5.0,3.0,20.512633841365776,CAR-T trial,RECRUITING in high urgency phase (PHASE2),clinicaltrials,trial_collaborator: Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukem | trial_collaborator: Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma | trial_collaborator: Her2-BATS and Pembrolizumab in Metastatic Breast Cancer,Pembro Plus CAR T-cell Therapy in R/R in PMBCL,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT05934448,A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006),RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT05458297,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
25,"PersonGen BioTherapeutics (Suzhou) Co., Ltd.",5.0,3.0,20.49922349186338,CAR-T trial,RECRUITING in high urgency phase (PHASE2),clinicaltrials,trial_collaborator: Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia,Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases,NOT_YET_RECRUITING,NA,https://clinicaltrials.gov/study/NCT06871644,PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT07188610,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
26,Takeda,5.0,3.0,20.49915094714656,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,"trial_collaborator: A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia | trial_collaborator: IVIG for Infection Prevention After CAR-T-Cell Therapy | trial_collaborator: Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positi",IVIG for Infection Prevention After CAR-T-Cell Therapy,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT05952804,A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT05748197,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
27,"Nanjing IASO Biotechnology Co., Ltd.",5.0,3.0,20.491643204309163,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies | trial_collaborator: A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | trial_collaborator: Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE),Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis,NOT_YET_RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT07055724,IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07309900,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
28,"Nanjing Bioheng Biotech Co., Ltd.",5.0,3.0,20.46431817651763,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases | trial_collaborator: CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia | trial_collaborator: RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies,Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases,RECRUITING,EARLY_PHASE1,https://clinicaltrials.gov/study/NCT06775912,CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06622694,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
29,"Hebei Taihe Chunyu Biotechnology Co., Ltd",5.0,3.0,20.412544238059283,CAR-T trial,"NOT_YET_RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,"trial_collaborator: Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human  | trial_collaborator: CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma | trial_collaborator: Autologous Transplantation Combined With BCMA CAR-T in the Treatment of Young NDMM","Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma",NOT_YET_RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT07259070,"Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma",NOT_YET_RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT07259070,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
30,Autolus Limited,5.0,3.0,20.398462215343162,CAR-T trial,RECRUITING in high urgency phase (PHASE2),clinicaltrials,trial_collaborator: A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia,A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL),ACTIVE_NOT_RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT04404660,A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT07400029,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
31,Bellicum Pharmaceuticals,5.0,3.0,20.37650347978633,CAR-T trial,"RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,trial_collaborator: Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer | trial_collaborator: Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC | trial_collaborator: Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refract,Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer,RECRUITING,EARLY_PHASE1,https://clinicaltrials.gov/study/NCT05620342,Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC,RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT06096038,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
32,iCell Gene Therapeutics,5.0,3.0,20.372240932759322,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia  | trial_collaborator: Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myel | trial_collaborator: CD4CAR for CD4+ Leukemia and Lymphoma,Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06197672,Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06197672,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
33,Allogene Therapeutics,5.0,3.0,20.37218732998655,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,,"A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease",RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07085104,"A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease",RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07085104,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
34,Juventas Cell Therapy Ltd.,5.0,3.0,20.370563400358606,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma | trial_collaborator: CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy. | trial_collaborator: Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute ,Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06676982,Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06676982,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
35,Bioray Laboratories,5.0,3.0,20.351110209329367,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC | trial_collaborator: Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System. | trial_collaborator: Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC,Universal CAR-T Cell Therapy for MM,RECRUITING,NA,https://clinicaltrials.gov/study/NCT07248176,The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT05741359,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
36,A2 Biotherapeutics Inc.,5.0,3.0,20.34813257413112,CAR-T trial,"RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,,Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing,RECRUITING,,https://clinicaltrials.gov/study/NCT04981119,"A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression",RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT06051695,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
37,"Poseida Therapeutics, Inc.",5.0,3.0,20.348132572921124,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,,P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06014762,P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06014762,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
38,Cartesian Therapeutics,5.0,3.0,20.34813256689145,CAR-T trial,NOT_YET_RECRUITING in high urgency phase (PHASE2),clinicaltrials,,"Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis",RECRUITING,PHASE3,https://clinicaltrials.gov/study/NCT06799247,Descartes-08 in Autoantibody Myositis,NOT_YET_RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT07391605,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
39,Cabaletta Bio,5.0,3.0,20.344851810536714,CAR-T trial,"RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,,"A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)",RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT04422912,RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis,RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT06359041,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
40,Fate Therapeutics,5.0,3.0,20.339118038186662,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,,"FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors",RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06241456,A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06308978,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
